AnaptysBio, Inc. ANAB Biopharma Company — Nonoperating Income Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by AnaptysBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about AnaptysBio, Inc.'s biopharma company — nonoperating income expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AnaptysBio, Inc.'s biopharma company — nonoperating income expense?
- AnaptysBio, Inc. (ANAB) reported biopharma company — nonoperating income expense of $2.33M in Q1 2026.
- How has AnaptysBio, Inc.'s biopharma company — nonoperating income expense changed year-over-year?
- AnaptysBio, Inc.'s biopharma company — nonoperating income expense decreased by 43.0% year-over-year, from $4.08M to $2.33M.
- What does biopharma company — nonoperating income expense mean?
- This metric aggregates all financial activities outside of the company's primary business operations, such as interest income, interest expense, and other non-operating items. It represents the net impact of the company's treasury and financing activities on its overall financial performance. This is a critical component for understanding the total net income or loss beyond operational results.